Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
08
12
2022
revised:
16
02
2023
accepted:
23
03
2023
medline:
2
6
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
Cancer survivors are at an increased risk of cardiovascular disease (CVD) compared with the general population. We sought to evaluate the impact of mosaic chromosomal alterations (mCA) on death of CVD causes, coronary artery disease (CAD) causes, and of any cause in patients with a cancer diagnosis. The study was a prospective cohort analysis of 48,919 UK Biobank participants with a cancer diagnosis. mCAs were characterized using DNA genotyping array intensity data and long-range chromosomal phase inference. Multivariable Cox regression models were used to ascertain the associations of mCAs. Exploratory endpoints included various incident cardiovascular phenotypes. Overall, 10,070 individuals (20.6%) carried ≥ 1 mCA clone. In adjusted analyses, mCA was associated with an increased risk of death of CAD causes [HR, 1.37; 95% confidence interval (CI), 1.09-1.71; P = 0.006]. In sub-analyses, we found that carriers of mCAs diagnosed with kidney cancer had an increased risk of death of CVD causes (HR, 2.03; 95% CI, 1.11-3.72; P = 0.022) and CAD causes (HR, 3.57; 95% CI, 1.44-8.84; P = 0.006). Women diagnosed with breast cancer who carried a mCA also had a higher risk of death of CAD causes (HR, 2.46; 95% CI, 1.23-4.92; P = 0.011). Among cancer survivors, carriers of any mCA are at an increased risk of CAD death compared with noncarriers. Mechanistic studies should be considered to better ascertain the biological mechanisms underneath the observed associations between mCAs and cardiovascular events for specific cancer types. There may be clinical relevance in considering mCAs in patients diagnosed with cancer and undergoing treatment.
Sections du résumé
BACKGROUND
Cancer survivors are at an increased risk of cardiovascular disease (CVD) compared with the general population. We sought to evaluate the impact of mosaic chromosomal alterations (mCA) on death of CVD causes, coronary artery disease (CAD) causes, and of any cause in patients with a cancer diagnosis.
METHODS
The study was a prospective cohort analysis of 48,919 UK Biobank participants with a cancer diagnosis. mCAs were characterized using DNA genotyping array intensity data and long-range chromosomal phase inference. Multivariable Cox regression models were used to ascertain the associations of mCAs. Exploratory endpoints included various incident cardiovascular phenotypes.
RESULTS
Overall, 10,070 individuals (20.6%) carried ≥ 1 mCA clone. In adjusted analyses, mCA was associated with an increased risk of death of CAD causes [HR, 1.37; 95% confidence interval (CI), 1.09-1.71; P = 0.006]. In sub-analyses, we found that carriers of mCAs diagnosed with kidney cancer had an increased risk of death of CVD causes (HR, 2.03; 95% CI, 1.11-3.72; P = 0.022) and CAD causes (HR, 3.57; 95% CI, 1.44-8.84; P = 0.006). Women diagnosed with breast cancer who carried a mCA also had a higher risk of death of CAD causes (HR, 2.46; 95% CI, 1.23-4.92; P = 0.011).
CONCLUSIONS
Among cancer survivors, carriers of any mCA are at an increased risk of CAD death compared with noncarriers. Mechanistic studies should be considered to better ascertain the biological mechanisms underneath the observed associations between mCAs and cardiovascular events for specific cancer types.
IMPACT
There may be clinical relevance in considering mCAs in patients diagnosed with cancer and undergoing treatment.
Identifiants
pubmed: 36976640
pii: 719076
doi: 10.1158/1055-9965.EPI-22-1290
pmc: PMC10233351
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
776-783Subventions
Organisme : CIHR
ID : 409752
Pays : Canada
Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.
Références
Lancet. 2018 Mar 10;391(10124):933
pubmed: 29536852
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
Am J Hum Genet. 2016 Jun 2;98(6):1208-1219
pubmed: 27231129
Science. 2022 Jul 15;377(6603):292-297
pubmed: 35857592
Curr Atheroscler Rep. 2022 Jun;24(6):443-456
pubmed: 35441347
Hypertension. 2021 Feb;77(2):367-375
pubmed: 33390054
Nature. 2020 Aug;584(7819):136-141
pubmed: 32581363
J Clin Oncol. 2010 Oct 20;28(30):4649-57
pubmed: 20855830
Nature. 2018 Oct;562(7726):203-209
pubmed: 30305743
Nature. 2018 Jul;559(7714):350-355
pubmed: 29995854
Nat Genet. 2012 May 06;44(6):642-50
pubmed: 22561516
Ann Oncol. 2003;14 Suppl 5:v128-49
pubmed: 14684503
Nat Genet. 2019 Jan;51(1):4-7
pubmed: 30374072
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
J Clin Oncol. 2016 Apr 1;34(10):1122-30
pubmed: 26834065
Cell Stem Cell. 2017 Sep 7;21(3):374-382.e4
pubmed: 28803919
Nat Genet. 2020 Nov;52(11):1219-1226
pubmed: 33106634
Circ Cardiovasc Genet. 2017 Aug;10(4):e001544
pubmed: 28768751
Semin Hematol. 2013 Oct;50(4):348-59
pubmed: 24246702
Arch Osteoporos. 2020 Jun 9;15(1):86
pubmed: 32519193
Nat Med. 2021 Jun;27(6):1012-1024
pubmed: 34099924
Am J Hum Genet. 2012 Feb 10;90(2):217-28
pubmed: 22305530
Nat Genet. 2014 Jun;46(6):624-8
pubmed: 24777449
Cell Biosci. 2021 Jul 23;11(1):143
pubmed: 34301302
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Nat Commun. 2016 Jun 13;7:11843
pubmed: 27291797
N Engl J Med. 2017 Jul 13;377(2):111-121
pubmed: 28636844
Nat Med. 2014 Dec;20(12):1472-8
pubmed: 25326804
Circulation. 2021 Feb 2;143(5):410-423
pubmed: 33161765
EBioMedicine. 2022 Apr;78:103964
pubmed: 35339897
J Autoimmun. 2012 May;38(2-3):J193-6
pubmed: 22196921
Circulation. 2020 Jan 14;141(2):124-131
pubmed: 31707836
Nat Genet. 2016 Nov;48(11):1443-1448
pubmed: 27694958
PLoS Med. 2015 Mar 31;12(3):e1001779
pubmed: 25826379
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
Lancet. 2022 Apr 16;399(10334):1537-1550
pubmed: 35430021
Nat Genet. 2012 May 06;44(6):651-8
pubmed: 22561519
Cell Rep. 2015 Mar 3;10(8):1239-45
pubmed: 25732814
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
Sci Rep. 2022 May 4;12(1):7248
pubmed: 35508625
Nat Genet. 2012 Nov;44(11):1179-81
pubmed: 23001125
Blood Adv. 2020 Jun 9;4(11):2430-2438
pubmed: 32492156
Sci Rep. 2018 Aug 17;8(1):12316
pubmed: 30120341
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582